{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021212","form_type":"8-K","ticker":"BCAB","cik":"0001826892","company_name":"BioAtla, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.929513+00:00","generated_at":"2026-06-15T04:41:36.859164+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BioAtla Q1 net loss $27.5M; cash $192.7M funds operations into 2025","bullets":["Cash and equivalents $192.7M as of March 31, 2023, down from $215.5M at Dec 31, 2022.","Net loss $27.5M vs $24.3M in Q1 2022; R&D expense rose to $21.7M from $16.9M.","Phase 2 potentially registrational BA3011 UPS study enrolling; LMS cohort readout expected 2H23.","FDA meeting request for BA3011 NSCLC Phase 2 part 2 on track for 1H23; initiation in 2H23.","BA3021 NSCLC interim readout and BA3071 Phase 1 data readout both on track for 2H23."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021212","json":"https://secwatch.observer/filing/0000950170-23-021212.json","markdown":"https://secwatch.observer/filing/0000950170-23-021212.md","text":"https://secwatch.observer/filing/0000950170-23-021212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826892/000095017023021212/0000950170-23-021212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826892/000095017023021212/bcab-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:41:36.859164+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}